Medicis is the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and podiatric conditions and aesthetics medicine. The Company is dedicated to helping patients attain a healthy and youthful appearance and self-image. Medicis has leading branded prescription products in a number of therapeutic categories, including acne, fungal infections, psoriasis, rosacea, seborrheic dermatitis, and skin and skin-structure infections. Additionally, the company markets the leading dermal filler in the U.S., Restylane.

The Company's products have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance.

New product developments, internal growth, acquisitions and strategic collaborations have driven the success and expansion of the Company. Careful execution of this strategy has yielded a compounded annual growth rate of approximately 21% over the past five fiscal years, and has provided uncommon stability in operating results.

With a balanced business in North America and an extraordinary track record of revenue, operating income growth and impressive gross profit margins, Medicis is driven to continue its success and assure long-term shareholder value.